<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23469080</article-id><article-id pub-id-type="pmc">3585222</article-id><article-id pub-id-type="publisher-id">PONE-D-12-31942</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0057830</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Pathology</subject><subj-group><subject>General Pathology</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group></subj-group><subj-group><subject>Oncology</subject><subj-group><subject>Basic Cancer Research</subject><subj-group><subject>Metastasis</subject></subj-group></subj-group><subj-group><subject>Cancer Treatment</subject><subj-group><subject>Chemotherapy and Drug Treatment</subject><subject>Radiation Therapy</subject></subj-group></subj-group><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Head and Neck Tumors</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>A Novel Statistical Prognostic Score Model That Includes Serum CXCL5 Levels and Clinical Classification Predicts Risk of Disease Progression and Survival of Nasopharyngeal Carcinoma Patients</article-title><alt-title alt-title-type="running-head">Prognositic C-C Model for Nasopharyngeal Carcinoma</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Haibo</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Xia</surname><given-names>Weixiong</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Xing</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Rui</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Lisheng</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Yanfang</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bao</surname><given-names>Yingna</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xiang</surname><given-names>Yanqun</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Xiang</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, China</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>State Key Laboratory of Oncology in Southern China, Guangzhou, China</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Samimi</surname><given-names>Goli</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Kinghorn Cancer Centre, Garvan Institute of Medical Research, Australia</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>guoxiang@sysucc.org.cn</email> (XG); <email>xiangyq@sysucc.org.cn</email> (YX)</corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: XG YX. Performed the experiments: LZ YB. Analyzed the data: HZ WX XL LW. Contributed reagents/materials/analysis tools: XL RS YY. Wrote the paper: HZ WX.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>28</day><month>2</month><year>2013</year></pub-date><volume>8</volume><issue>2</issue><elocation-id>e57830</elocation-id><history><date date-type="received"><day>18</day><month>10</month><year>2012</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 Zhang et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Zhang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Aberrant expression of C-X-C motif chemokine 5 (CXCL5) contributes to the progression of various cancers. This study analyzed the clinical significance of serum CXCL5 (sCXCL5) levels of nasopharyngeal carcinoma (NPC) patients, with the goal of building a novel prognostic score model.</p></sec><sec><title>Experimental Design</title><p>Serum samples were collected prior to treatment from 290 NPC patients for the detection of sCXCL5 with ELISA. Half of the patients (n&#x0200a;=&#x0200a;145) were randomly assigned to the training set to generate the sCXCL5 cutoff point using receiver operator characteristic (ROC) analysis, while the other half (n&#x0200a;=&#x0200a;145) were assigned to the testing set for validation. Associations between sCXCL5 levels and clinical characteristics were analyzed. A prognostic score model was built using independent predictors derived from multivariate analysis. A concordance index (C-Index) was used to evaluate prognostic ability.</p></sec><sec><title>Results</title><p>The sCXCL5 cutoff point was 0.805 ng/ml. Sex, age, histology, T classification, clinical classification and local recurrence were not associated with sCXCL5 levels. However, sCXCL5 levels were positively associated with N classification, distant metastasis and disease progression (<italic>P</italic>&#x0003c;0.05). A high sCXCL5 level predicted poor 6-year overall survival (OS), poor 6-year distant metastasis-free survival (DMFS), and poor 6-year progression-free survival (PFS). A prognostic score model was subsequently constructed based on sCXCL5 levels and clinical classification (C-C model), which are independent predictors of OS, DMFS, and PFS, as confirmed by the multivariate analysis. Furthermore, this novel model successfully divided the patients into four risk subgroups in the training set, the testing set and the entire set of patients. The C-Indices were 0.751 and 0.762 for the training set and the testing set, respectively.</p></sec><sec><title>Conclusions</title><p>sCXCL5 level was determined to be an independent prognostic factor for NPC patients. The novel statistical C-C model, which includes sCXCL5 levels and clinical classification, could be helpful in predicting the prognosis of NPC patients.</p></sec></abstract><funding-group><funding-statement>This work was supported by National Natural Science Foundation of China (No: 81172041; 81201630) and Natural Science Foundation of Guangdong Province (No: S2011010005312). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Nasopharyngeal carcinoma (NPC) is the most common cancer originating from the nasopharynx. NPC differs significantly from other head and neck cancers in terms of its high rate of distant metastasis, undifferentiated histology, radiosensitivity and chemosensitivity. The highest incidence of NPC is found in Southeast Asia, especially in the Guangdong Province of China <xref rid="pone.0057830-Wei1" ref-type="bibr">[1]</xref>. One of the significant risk factors for NPC is Epstein-Barr virus infection. This infection initiates a multi-step process that eventually progresses to the development of NPC <xref rid="pone.0057830-Fang1" ref-type="bibr">[2]</xref>, <xref rid="pone.0057830-Endo1" ref-type="bibr">[3]</xref>.</p><p>Enlarged cervical lymph nodes are the initial presentation in many NPC patients. Thus, NPC is usually diagnosed as a lymph node-metastatic disease. While NPC is relatively radiosensitive and chemosensitive, local-regional failure and distant metastasis are still the leading causes of treatment failure in this disease. With the development of irradiation techniques and chemoradiotherapy, the local-regional control rate for NPC has improved greatly in the past few decades, but the incidence of distant metastases has not decreased significantly <xref rid="pone.0057830-Lee1" ref-type="bibr">[4]</xref>, <xref rid="pone.0057830-Lai1" ref-type="bibr">[5]</xref>, reaching rates as high as 19% to 25% <xref rid="pone.0057830-Ma1" ref-type="bibr">[6]</xref>&#x02013;<xref rid="pone.0057830-Mao1" ref-type="bibr">[10]</xref>. A clinical classification system is commonly used in clinical practice to predict the outcome of NPC cases. In addition to the clinical classification system, an increasing number of biomarkers have been used to more precisely assess the prognoses of NPC patients. However, patients with the same clinical classification might have different prognoses after receiving a similar treatment. Therefore, there is a growing need for a novel prognostic model that utilizes both biomarkers and clinical classification to identify those patients with a poor prognosis before treatment and permit the use of much more aggressive treatment to improve overall survival.</p><p>Inflammation plays an important role in cancer development and progression. C-X-C motif chemokine 5 (CXCL5; formerly epithelial neutrophil-activating peptide-78 or ENA-78) is a member of the CXC chemokine family. CXCL5 induces the chemotaxis of neutrophils, promotes angiogenesis, and is involved in the remodeling of connective tissue <xref rid="pone.0057830-Walz1" ref-type="bibr">[11]</xref>, <xref rid="pone.0057830-Koch1" ref-type="bibr">[12]</xref>. Recently, CXCL5 was shown to promote the proliferation, migration, and invasion of various tumor cells <italic>in vitro</italic> and <italic>in vi</italic>vo <xref rid="pone.0057830-Kuo1" ref-type="bibr">[13]</xref>&#x02013;<xref rid="pone.0057830-Zhou1" ref-type="bibr">[16]</xref>. For example, CXCL5 is overexpressed in oral squamous cell carcinoma, colorectal cancer, hepatocellular cancer, prostate cancer, gastric cancer and pancreatic cancer <xref rid="pone.0057830-Miyazaki1" ref-type="bibr">[14]</xref>&#x02013;<xref rid="pone.0057830-Baier1" ref-type="bibr">[20]</xref>, with overexpression being associated with poor patient survival <xref rid="pone.0057830-Kawamura1" ref-type="bibr">[15]</xref>&#x02013;<xref rid="pone.0057830-Li1" ref-type="bibr">[17]</xref>. However, the association between serum CXCL5 (sCXCL5) expression and the prognosis of NPC patients is unclear.</p><p>In this study, we determined the sCXCL5 concentrations of 290 non-metastatic NPC patients before treatment and analyzed the associations between sCXCL5 concentrations and clinicopathological characteristics and prognosis. Based on these data, we constructed a novel prognostic score model based on clinical classification and sCXCL5 levels to predict the prognosis of NPC patients.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Patient Selection and Serum Collection</title><p>The Clinical Ethics Review Board of Sun Yat-Sen University Cancer Center approved this study. All of the patients signed informed consent documents prior to participating in this study.</p><p>Two hundred and ninety consecutive NPC patients who were newly diagnosed between July 2003 and August 2005 were recruited from Sun Yat-Sen University Cancer Center for this study. The eligibility criteria for inclusion in the study were as follows: an age of 18&#x02013;65 years, pathological confirmation of undifferentiated non-keratinized or differentiated non-keratinized carcinoma of the nasopharynx, a Union for International Cancer Control (UICC) staging system 2002 clinical classification of I to IVb. The exclusion criteria included a history of anticancer therapy, pregnancy or lactation, and the presence of contraindications for receiving chemotherapy or radiotherapy.</p><p>Blood samples were obtained by venipuncture prior to anticancer therapy, centrifuged at 3000 rpm for 10 min and then frozen at &#x02013;80&#x000b0;C until analysis.</p></sec><sec id="s2b"><title>Pretreatment Evaluation of the Patients</title><p>All of the patients underwent a pretreatment evaluation that included a precise clinical examination of the head and neck region, fiber optic nasopharyngoscopy, head and neck MRI, chest X-ray, ultrasonography of the abdominal region, bone scan, and a complete blood count and biochemical profile.</p></sec><sec id="s2c"><title>Patient Treatment</title><p>All of the patients received continuous definitive radiotherapy consisting of 2 Gy/fraction/day, five days/week. This therapy was delivered by a linear accelerator (6&#x02013;8 MV) for 6&#x02013;8 weeks. The range of radiation doses delivered to the primary tumor site was 60&#x02013;78 Gy, while the doses delivered to the lymph node-positive regions and the lymph node-negative areas ranged from 60&#x02013;70 Gy and 50&#x02013;60 Gy, respectively.</p><p>In addition to radiotherapy, 236 patients with class III, IVa, or IVb disease received platinum-based chemotherapy. Of this group, 90 patients received inductive chemotherapy and radiotherapy, 55 patients received concurrent chemoradiotherapy, and 91 patients received inductive chemotherapy and concurrent chemoradiotherapy. Inductive chemotherapy consisted of 2 cycles of 5-&#x0fb02;uorouracil (4 g/m<sup>2</sup>) and cisplatin (80 mg/m<sup>2</sup>) every 3 weeks. Concurrent chemoradiotherapy consisted of 2 to 3 cycles of high-dose cisplatin (80 mg/m<sup>2</sup>) for 3 weeks. Four of the patients with class III disease refused chemotherapy and received radiotherapy only, and 1 patient with class II disease received concurrent chemoradiotherapy.</p></sec><sec id="s2d"><title>Patient Follow-up</title><p>After the completion of therapy, all of the patients attended follow-up visits at 3-month intervals for the first 3 years, every 6 months for the fourth and fifth years, and annually thereafter. The primary end point of the study was overall survival (OS). The secondary end points were distant metastasis-free survival (DMFS), local&#x02013;regional recurrence-free survival (LRRFS) and progression-free survival (PFS). These end points were defined as follows: OS, survival during the follow-up period; DMFS, survival without distant metastasis; LRRFS, survival without persistence or recurrence in the nasopharynx or cervical lymph nodes; and PFS, survival without local-regional failure or distant metastasis.</p></sec><sec id="s2e"><title>ELISA Detection of sCXCL5 Levels</title><p>Serum CXCL5levels were measured with a commercially available ELISA kit (Quantikine Human ENA-78; R&#x00026;D Systems, Minneapolis, MN, USA) in accordance with the manufacturer&#x02019;s instructions. The measurements were performed in triplicate, and the data were summarized as the mean&#x000b1;SD.</p></sec><sec id="s2f"><title>Statistical Analyses</title><p>The Statistical Package for Social Sciences, version 16.0 (SPSS, Chicago, IL, USA) was used for all of the statistical analyses and for the generation of a random number table for assigning patients to either the training or testing sets. A receiver operating characteristic (ROC) curve analysis was subjected to the selection of cutoff points of sCXCL5 concentration for OS. The chi-squared test was employed to compare data among groups. Cumulative survival rates were set with the life-table method. Differences in survival probabilities were determined by Kaplan-Meier analysis and the log-rank test. A multivariate analysis was performed with the Cox proportional hazards model (enter method) to analyze the factors related to prognosis. All of the statistical tests were two-sided, and <italic>P</italic>-values&#x0003c;0.05 were considered statistically significant. For the analyses involving multiple testing, adjusted <italic>P</italic>-values&#x0003c;0.017 were considered statistically significant.</p><p>One hundred and forty-five of the 290 patients were randomly assigned to the training set, which was used to generate the sCXCL5 cutoff point, evaluate the prognostic factors, and develop a prognostic score model. The remaining 145 patients were assigned to the testing set for data validation.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Patient Clinical Characteristics</title><p>The latest patient follow-up visit occurred in May 2012. The time range for follow-up visits was between 8 and 105 months, with a median of 80 months. The follow-up rates at 1, 3, and 6 years were 100%, 100%, and 94.827%, respectively. One hundred and six patients died during the follow-up period, with 101 patients dying due to local-regional relapse and/or distant metastasis and 5 dying of non-neoplastic diseases. A total of 123 patients experienced disease recurrence: 73 developed distant metastasis, 40 developed local-regional relapse, and 10 developed both distant metastasis and local-regional relapse. The most frequent metastatic sites were the bone, liver, and lung, occurring in 29, 20, and 14 patients, respectively. Nineteen patients suffered from multiple organ metastases, and 1 patient had metastasis to the mediastinal and retroperitoneal lymph nodes. The clinicopathological characteristics of the 290 patients are summarized in <xref ref-type="table" rid="pone-0057830-t001">Table 1</xref>.</p><table-wrap id="pone-0057830-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057830.t001</object-id><label>Table 1</label><caption><title>The clinicopathological characteristics of the NPC patients in the training and testing sets and their association with sCXCL5 levels.</title></caption><alternatives><graphic id="pone-0057830-t001-1" xlink:href="pone.0057830.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">All patients</td><td colspan="3" align="left" rowspan="1">Training set (n&#x0200a;=&#x0200a;145)</td><td colspan="3" align="left" rowspan="1">Testing set (n&#x0200a;=&#x0200a;145)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n&#x0200a;=&#x0200a;290 (%)</td><td align="left" rowspan="1" colspan="1">High (%)(n&#x0200a;=&#x0200a;75)</td><td align="left" rowspan="1" colspan="1">Low (%)(n&#x0200a;=&#x0200a;70)</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
</td><td align="left" rowspan="1" colspan="1">High (%)(n&#x0200a;=&#x0200a;90)</td><td align="left" rowspan="1" colspan="1">Low (%)(n&#x0200a;=&#x0200a;55)</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1"/><td colspan="6" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;50</td><td align="left" rowspan="1" colspan="1">199 (69)</td><td align="left" rowspan="1" colspan="1">53 (71)</td><td align="left" rowspan="1" colspan="1">49 (70)</td><td align="left" rowspan="1" colspan="1">0.930</td><td align="left" rowspan="1" colspan="1">59 (65)</td><td align="left" rowspan="1" colspan="1">38 (69)</td><td align="left" rowspan="1" colspan="1">0.661</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265; 50</td><td align="left" rowspan="1" colspan="1">91 (31)</td><td align="left" rowspan="1" colspan="1">22 (29)</td><td align="left" rowspan="1" colspan="1">21 (30)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">31 (35)</td><td align="left" rowspan="1" colspan="1">17 (31)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1"/><td colspan="6" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">204 (70)</td><td align="left" rowspan="1" colspan="1">53 (71)</td><td align="left" rowspan="1" colspan="1">50 (71)</td><td align="left" rowspan="1" colspan="1">0.919</td><td align="left" rowspan="1" colspan="1">61 (68)</td><td align="left" rowspan="1" colspan="1">40 (73)</td><td align="left" rowspan="1" colspan="1">0.529</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">86 (30)</td><td align="left" rowspan="1" colspan="1">22 (29)</td><td align="left" rowspan="1" colspan="1">20 (29)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">29 (32)</td><td align="left" rowspan="1" colspan="1">15 (27)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histological type</td><td align="left" rowspan="1" colspan="1"/><td colspan="6" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">D</td><td align="left" rowspan="1" colspan="1">36 (12)</td><td align="left" rowspan="1" colspan="1">9 (12)</td><td align="left" rowspan="1" colspan="1">7 (10)</td><td align="left" rowspan="1" colspan="1">0.190</td><td align="left" rowspan="1" colspan="1">13 (14)</td><td align="left" rowspan="1" colspan="1">7 (13)</td><td align="left" rowspan="1" colspan="1">0.771</td></tr><tr><td align="left" rowspan="1" colspan="1">U</td><td align="left" rowspan="1" colspan="1">254 (88)</td><td align="left" rowspan="1" colspan="1">66 (88)</td><td align="left" rowspan="1" colspan="1">63 (90)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">77 (86)</td><td align="left" rowspan="1" colspan="1">48 (87)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tumor classification</td><td align="left" rowspan="1" colspan="1"/><td colspan="6" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T1&#x02013;2</td><td align="left" rowspan="1" colspan="1">79 (27)</td><td align="left" rowspan="1" colspan="1">2 4(32)</td><td align="left" rowspan="1" colspan="1">22 (31)</td><td align="left" rowspan="1" colspan="1">0.941</td><td align="left" rowspan="1" colspan="1">23 (26)</td><td align="left" rowspan="1" colspan="1">10 (18)</td><td align="left" rowspan="1" colspan="1">0.304</td></tr><tr><td align="left" rowspan="1" colspan="1">T3&#x02013;4</td><td align="left" rowspan="1" colspan="1">211 (73)</td><td align="left" rowspan="1" colspan="1">51 (68)</td><td align="left" rowspan="1" colspan="1">48 (69)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">67 (74)</td><td align="left" rowspan="1" colspan="1">45 (82)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nodal classification</td><td align="left" rowspan="1" colspan="1"/><td colspan="6" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N0&#x02013;1</td><td align="left" rowspan="1" colspan="1">156 (54)</td><td align="left" rowspan="1" colspan="1">35 (47)</td><td align="left" rowspan="1" colspan="1">45 (64)</td><td align="left" rowspan="1" colspan="1">0.033</td><td align="left" rowspan="1" colspan="1">41 (46)</td><td align="left" rowspan="1" colspan="1">35 (64)</td><td align="left" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" rowspan="1" colspan="1">N2&#x02013;3</td><td align="left" rowspan="1" colspan="1">134 (46)</td><td align="left" rowspan="1" colspan="1">40 (53)</td><td align="left" rowspan="1" colspan="1">25 (36)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">49 (54)</td><td align="left" rowspan="1" colspan="1">20 (36)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Clinical classification</td><td align="left" rowspan="1" colspan="1"/><td colspan="6" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">I&#x02013;II</td><td align="left" rowspan="1" colspan="1">50 (17)</td><td align="left" rowspan="1" colspan="1">12 (16)</td><td align="left" rowspan="1" colspan="1">16 (23)</td><td align="left" rowspan="1" colspan="1">0.296</td><td align="left" rowspan="1" colspan="1">14 (16)</td><td align="left" rowspan="1" colspan="1">8 (15)</td><td align="left" rowspan="1" colspan="1">0.869</td></tr><tr><td align="left" rowspan="1" colspan="1">III&#x02013;IVb</td><td align="left" rowspan="1" colspan="1">240 (83)</td><td align="left" rowspan="1" colspan="1">63 (84)</td><td align="left" rowspan="1" colspan="1">54 (77)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">76 (84)</td><td align="left" rowspan="1" colspan="1">47 (85)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Chemotherapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">53 (18)</td><td align="left" rowspan="1" colspan="1">12 (16)</td><td align="left" rowspan="1" colspan="1">15 (21)</td><td align="left" rowspan="1" colspan="1">0.527</td><td align="left" rowspan="1" colspan="1">16 (18)</td><td align="left" rowspan="1" colspan="1">10 (18)</td><td align="left" rowspan="1" colspan="1">0.292</td></tr><tr><td align="left" rowspan="1" colspan="1">Inductive</td><td align="left" rowspan="1" colspan="1">90 (31)</td><td align="left" rowspan="1" colspan="1">21 (28)</td><td align="left" rowspan="1" colspan="1">19 (27)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">28 (31)</td><td align="left" rowspan="1" colspan="1">22 (40)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Concurrent</td><td align="left" rowspan="1" colspan="1">56 (19)</td><td align="left" rowspan="1" colspan="1">13 (17)</td><td align="left" rowspan="1" colspan="1">16 (23)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">21 (23)</td><td align="left" rowspan="1" colspan="1">6 (11)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Inductive+ concurrent</td><td align="left" rowspan="1" colspan="1">91 (31)</td><td align="left" rowspan="1" colspan="1">29 (39)</td><td align="left" rowspan="1" colspan="1">20 (29)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">25 (28)</td><td align="left" rowspan="1" colspan="1">17 (31)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Local&#x02013;regional recurrence</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">240 (83)</td><td align="left" rowspan="1" colspan="1">58 (77)</td><td align="left" rowspan="1" colspan="1">55 (79)</td><td align="left" rowspan="1" colspan="1">0.857</td><td align="left" rowspan="1" colspan="1">76 (84)</td><td align="left" rowspan="1" colspan="1">51 (92)</td><td align="left" rowspan="1" colspan="1">0.142</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">50 (17)</td><td align="left" rowspan="1" colspan="1">17 (23)</td><td align="left" rowspan="1" colspan="1">15 (21)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">14 (16)</td><td align="left" rowspan="1" colspan="1">4 (7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Distant metastasis</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">207 (71)</td><td align="left" rowspan="1" colspan="1">47 (63)</td><td align="left" rowspan="1" colspan="1">57 (81)</td><td align="left" rowspan="1" colspan="1">0.012</td><td align="left" rowspan="1" colspan="1">58 (64)</td><td align="left" rowspan="1" colspan="1">45 (82)</td><td align="left" rowspan="1" colspan="1">0.025</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">83 (29)</td><td align="left" rowspan="1" colspan="1">28 (37)</td><td align="left" rowspan="1" colspan="1">13 (19)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">32 (36)</td><td align="left" rowspan="1" colspan="1">10 (18)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Progression</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">167 (58)</td><td align="left" rowspan="1" colspan="1">32 (43)</td><td align="left" rowspan="1" colspan="1">44 (63)</td><td align="left" rowspan="1" colspan="1">0.015</td><td align="left" rowspan="1" colspan="1">49 (54)</td><td align="left" rowspan="1" colspan="1">42 (76)</td><td align="left" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">123 (42)</td><td align="left" rowspan="1" colspan="1">43 (57)</td><td align="left" rowspan="1" colspan="1">26 (37)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">41 (46)</td><td align="left" rowspan="1" colspan="1">13 (24)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Abbreviations: NPC, nasopharyngeal carcinoma; sCXCL5, serum CXCL5; D, differentiated non-keratinized carcinoma; U, undifferentiated non-keratinized carcinoma.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Relationship between sCXCL5 Levels and Clinical Characteristics of NPC Patients</title><p>The sCXCL5 concentrations in the 290 NPC patients ranged from 0.135 ng/ml to 3.058 ng/ml, with a mean of 0.980&#x000b1;0.48 ng/ml and a median of 0.828 ng/ml. We used the training set to construct ROC curves for death events and censors to identify the impact of sCXCL5 levels on the survival of NPC patients, selecting 0.805 ng/ml as the cutoff point for the subsequent binary variable analysis. Sex, age, histological type, T classification, clinical classification and local recurrence had no impact on sCXCL5 levels. However, the sCXCL5 level was positively associated with advanced N classification, distant metastasis and disease progression (<italic>P</italic>&#x0003c;0.05). A similar association was verified in the testing set (<xref ref-type="table" rid="pone-0057830-t001">Table 1</xref>).</p></sec><sec id="s3c"><title>Serum CXCL5 Levels in Predicting the Survival of NPC Patients</title><p>In the training set, the 6-year-OS rates for the low sCXCL5 level group and the high sCXCL5 level group were 75% and 54%, respectively (<italic>P</italic>&#x0200a;=&#x0200a;0.034). The 6-year-DMFS rates for the low sCXCL5 level group and the high sCXCL5 level group were 82% and 63% (<italic>P</italic>&#x0200a;=&#x0200a;0.014), respectively (<xref ref-type="fig" rid="pone-0057830-g001">Figure 1</xref> shows the complete follow-up). The 6-year-PFS rates for the low sCXCL5 level group and the high sCXCL5 level group were 65% and 45% (<italic>P</italic>&#x0200a;=&#x0200a;0.021), respectively. However, there were no significant differences in the 6-year-LRRFS rates of the two groups, with 75% and 77% (<italic>P</italic>&#x0200a;=&#x0200a;0.955) LRRFS rates for the high and low sCXCL5 level groups, respectively.</p><fig id="pone-0057830-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057830.g001</object-id><label>Figure 1</label><caption><title>The survival curves for the nasopharyngeal carcinoma patients with high/low serum CXCL5-levels in the training set.</title><p>A high sCXCL5 level correlated with poor overall survival and distant metastasis-free survival rates in the training set patients. (A) The overall survival rate was significantly higher in the low sCXCL5 level patients; (B) The distant metastasis-free survival rate was significantly higher in the low sCXCL5 level patients. Low sCXCL5 level, n&#x0200a;=&#x0200a;70; high sCXCL5 level, n&#x0200a;=&#x0200a;75.</p></caption><graphic xlink:href="pone.0057830.g001"/></fig></sec><sec id="s3d"><title>Cox Proportional Hazards Model Analyses</title><p>Cox proportional hazards model was used for univariate analyses to determine if age, gender, histologic type, T classification, N classification, clinical classification, or sCXCL5 level was a prognostic factor for OS, DMFS or PFS in the training set. The results showed that T classification, N classification, clinical classification and sCXCL5 levels were significantly associated with OS, DMFS, and PFS in NPC patients (<xref ref-type="table" rid="pone-0057830-t002">Table 2</xref>).</p><table-wrap id="pone-0057830-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057830.t002</object-id><label>Table 2</label><caption><title>Univariate analysis with the Cox proportional hazards model for the OS, DMFS, and PFS of the NPC patients in the training set (n&#x0200a;=&#x0200a;145).</title></caption><alternatives><graphic id="pone-0057830-t002-2" xlink:href="pone.0057830.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Prognosis</td><td align="left" rowspan="1" colspan="1">Wald</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
</td><td align="left" rowspan="1" colspan="1">Exp(B)</td><td colspan="4" align="left" rowspan="1">95% CI for Exp(B)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Lower</td><td colspan="3" align="left" rowspan="1">Upper</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">OS</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1"/><td colspan="2" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years) &#x02265;50 vs.&#x0003c;50</td><td align="left" rowspan="1" colspan="1">1.191</td><td align="left" rowspan="1" colspan="1">0.273</td><td align="left" rowspan="1" colspan="1">1.372</td><td colspan="2" align="left" rowspan="1">0.779</td><td colspan="2" align="left" rowspan="1">2.417</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender Female vs. Male</td><td align="left" rowspan="1" colspan="1">0.530</td><td align="left" rowspan="1" colspan="1">0.462</td><td align="left" rowspan="1" colspan="1">0.799</td><td colspan="2" align="left" rowspan="1">0.440</td><td colspan="2" align="left" rowspan="1">1.452</td></tr><tr><td align="left" rowspan="1" colspan="1">Histological type U vs. D</td><td align="left" rowspan="1" colspan="1">0.152</td><td align="left" rowspan="1" colspan="1">0.701</td><td align="left" rowspan="1" colspan="1">0.852</td><td colspan="2" align="left" rowspan="1">0.376</td><td colspan="2" align="left" rowspan="1">1.931</td></tr><tr><td align="left" rowspan="1" colspan="1">T classification T2-4 vs. T1</td><td align="left" rowspan="1" colspan="1">20.923</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">2.284</td><td colspan="2" align="left" rowspan="1">1.603</td><td colspan="2" align="left" rowspan="1">3.255</td></tr><tr><td align="left" rowspan="1" colspan="1">N classification N1-3vs. N0</td><td align="left" rowspan="1" colspan="1">12.529</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">1.765</td><td colspan="2" align="left" rowspan="1">1.288</td><td colspan="2" align="left" rowspan="1">2.417</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical classification II-IVb vs. I</td><td align="left" rowspan="1" colspan="1">25.912</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">3.249</td><td colspan="2" align="left" rowspan="1">2.067</td><td colspan="2" align="left" rowspan="1">5.106</td></tr><tr><td align="left" rowspan="1" colspan="1">sCXCL5 level High vs. Low</td><td align="left" rowspan="1" colspan="1">5.893</td><td align="left" rowspan="1" colspan="1">0.015</td><td align="left" rowspan="1" colspan="1">2.013</td><td colspan="2" align="left" rowspan="1">1.148</td><td colspan="2" align="left" rowspan="1">3.529</td></tr><tr><td align="left" rowspan="1" colspan="1">DMFS</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1"/><td colspan="2" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years) &#x02265;50 vs.&#x0003c;50</td><td align="left" rowspan="1" colspan="1">0.374</td><td align="left" rowspan="1" colspan="1">0.541</td><td align="left" rowspan="1" colspan="1">0.796</td><td colspan="2" align="left" rowspan="1">0.384</td><td colspan="2" align="left" rowspan="1">1.652</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender Female vs. Male</td><td align="left" rowspan="1" colspan="1">0.111</td><td align="left" rowspan="1" colspan="1">0.739</td><td align="left" rowspan="1" colspan="1">1.119</td><td colspan="2" align="left" rowspan="1">0.577</td><td colspan="2" align="left" rowspan="1">2.171</td></tr><tr><td align="left" rowspan="1" colspan="1">Histological type U vs. D</td><td align="left" rowspan="1" colspan="1">0.111</td><td align="left" rowspan="1" colspan="1">0.739</td><td align="left" rowspan="1" colspan="1">0.848</td><td colspan="2" align="left" rowspan="1">0.320</td><td colspan="2" align="left" rowspan="1">2.243</td></tr><tr><td align="left" rowspan="1" colspan="1">T classification T2-4 vs. T1</td><td align="left" rowspan="1" colspan="1">2.698</td><td align="left" rowspan="1" colspan="1">0.100<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">1.346</td><td colspan="2" align="left" rowspan="1">0.944</td><td colspan="2" align="left" rowspan="1">1.920</td></tr><tr><td align="left" rowspan="1" colspan="1">N classification N1-3 vs. N0</td><td align="left" rowspan="1" colspan="1">35.143</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">3.342</td><td colspan="2" align="left" rowspan="1">2.243</td><td colspan="2" align="left" rowspan="1">4.981</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical classification II-IVb vs. I</td><td align="left" rowspan="1" colspan="1">7.949</td><td align="left" rowspan="1" colspan="1">0.005<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">1.958</td><td colspan="2" align="left" rowspan="1">1.227</td><td colspan="2" align="left" rowspan="1">3.124</td></tr><tr><td align="left" rowspan="1" colspan="1">sCXCL5 level High vs. Low</td><td align="left" rowspan="1" colspan="1">5.322</td><td align="left" rowspan="1" colspan="1">0.021</td><td align="left" rowspan="1" colspan="1">2.209</td><td colspan="2" align="left" rowspan="1">1.127</td><td colspan="2" align="left" rowspan="1">4.330</td></tr><tr><td align="left" rowspan="1" colspan="1">PFS</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1"/><td colspan="2" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years) &#x02265;50 vs.&#x0003c;50</td><td align="left" rowspan="1" colspan="1">0.102</td><td align="left" rowspan="1" colspan="1">0.749</td><td align="left" rowspan="1" colspan="1">0.916</td><td colspan="2" align="left" rowspan="1">0.533</td><td colspan="2" align="left" rowspan="1">1.572</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender Female vs. Male</td><td align="left" rowspan="1" colspan="1">0.157</td><td align="left" rowspan="1" colspan="1">0.692</td><td align="left" rowspan="1" colspan="1">0.898</td><td colspan="2" align="left" rowspan="1">0.529</td><td colspan="2" align="left" rowspan="1">1.525</td></tr><tr><td align="left" rowspan="1" colspan="1">Histological type U vs. D</td><td align="left" rowspan="1" colspan="1">0.359</td><td align="left" rowspan="1" colspan="1">0.549</td><td align="left" rowspan="1" colspan="1">0.800</td><td colspan="2" align="left" rowspan="1">0.385</td><td colspan="2" align="left" rowspan="1">1.661</td></tr><tr><td align="left" rowspan="1" colspan="1">T classification T2-4 vs. T1</td><td align="left" rowspan="1" colspan="1">13.884</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">1.731</td><td colspan="2" align="left" rowspan="1">1.297</td><td colspan="2" align="left" rowspan="1">2.309</td></tr><tr><td align="left" rowspan="1" colspan="1">N classification N1-3 vs. N0</td><td align="left" rowspan="1" colspan="1">21.655</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">1.988</td><td colspan="2" align="left" rowspan="1">1.488</td><td colspan="2" align="left" rowspan="1">2.656</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical classification II-IVb vs. I</td><td align="left" rowspan="1" colspan="1">19.064</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">2.249</td><td colspan="2" align="left" rowspan="1">1.563</td><td colspan="2" align="left" rowspan="1">3.237</td></tr><tr><td align="left" rowspan="1" colspan="1">sCXCL5 level High vs. Low</td><td align="left" rowspan="1" colspan="1">5.504</td><td align="left" rowspan="1" colspan="1">0.019</td><td align="left" rowspan="1" colspan="1">1.819</td><td colspan="2" align="left" rowspan="1">1.103</td><td colspan="2" align="left" rowspan="1">2.998</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>&#x025b3;, adjusted P-values &#x0003c;0.017 were considered statistically significant. Abbreviations: OS, overall survival; DMFS, distant metastasis-free survival; PFS, progression-free survival; NPC, nasopharyngeal carcinoma; sCXCL5, serum CXCL5; D, differentiated non-keratinized carcinoma; U, undifferentiated non-keratinized carcinoma; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><p>Multivariate analyses using the Cox proportional hazards model was further conducted in the training set to determine the independent prognostic factors of NPC patients, including all of the factors analyzed in the univariate analysis. The results showed that T classification, N classification, and sCXCL5 levels were independent predictors of OS.</p><p>The overlap between clinical classification and T/N classification required the application of further Cox proportional hazards model analyses, which included clinical classification but not T classification or N classification, as well as the rest of the clinical characteristics, to the training set. The results showed that both clinical classification and sCXCL5 level were independent predictors of OS (<italic>P</italic>&#x0003c;0.05, <xref ref-type="table" rid="pone-0057830-t003">Table 3</xref>).</p><table-wrap id="pone-0057830-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057830.t003</object-id><label>Table 3</label><caption><title>Multivariate analysis with the Cox proportional hazards model for the OS of the NPC patients in the training set (n&#x0200a;=&#x0200a;145).</title></caption><alternatives><graphic id="pone-0057830-t003-3" xlink:href="pone.0057830.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Analysis</td><td align="left" rowspan="1" colspan="1">Prognosis</td><td align="left" rowspan="1" colspan="1">Wald</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
</td><td align="left" rowspan="1" colspan="1">Exp(B)</td><td colspan="2" align="left" rowspan="1">95% CI for Exp(B)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Lower</td><td align="left" rowspan="1" colspan="1">Upper</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">OS</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Age (years) &#x02265;50 vs.&#x0003c;50</td><td align="left" rowspan="1" colspan="1">2.780</td><td align="left" rowspan="1" colspan="1">0.095</td><td align="left" rowspan="1" colspan="1">1.620</td><td align="left" rowspan="1" colspan="1">0.919</td><td align="left" rowspan="1" colspan="1">2.857</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Gender Female vs. Male</td><td align="left" rowspan="1" colspan="1">0.095</td><td align="left" rowspan="1" colspan="1">0.759</td><td align="left" rowspan="1" colspan="1">0.911</td><td align="left" rowspan="1" colspan="1">0.503</td><td align="left" rowspan="1" colspan="1">1.649</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Histological type U vs. D</td><td align="left" rowspan="1" colspan="1">0.410</td><td align="left" rowspan="1" colspan="1">0.522</td><td align="left" rowspan="1" colspan="1">0.769</td><td align="left" rowspan="1" colspan="1">0.343</td><td align="left" rowspan="1" colspan="1">1.720</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">T classification T2-4 vs. T1</td><td align="left" rowspan="1" colspan="1">6.939</td><td align="left" rowspan="1" colspan="1">0.008<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">2.584</td><td align="left" rowspan="1" colspan="1">1.275</td><td align="left" rowspan="1" colspan="1">5.237</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">N classification N1-3 vs. N0</td><td align="left" rowspan="1" colspan="1">11.823</td><td align="left" rowspan="1" colspan="1">0.001<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">2.025</td><td align="left" rowspan="1" colspan="1">1.354</td><td align="left" rowspan="1" colspan="1">3.027</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical classification II- IVb vs. I</td><td align="left" rowspan="1" colspan="1">0.163</td><td align="left" rowspan="1" colspan="1">0.686<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">1.191</td><td align="left" rowspan="1" colspan="1">0.510</td><td align="left" rowspan="1" colspan="1">2.778</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">sCXCL5 level High vs. Low</td><td align="left" rowspan="1" colspan="1">5.834</td><td align="left" rowspan="1" colspan="1">0.016</td><td align="left" rowspan="1" colspan="1">2.014</td><td align="left" rowspan="1" colspan="1">1.141</td><td align="left" rowspan="1" colspan="1">3.553</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">OS</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Age (years) &#x02265;50 vs.&#x0003c;50</td><td align="left" rowspan="1" colspan="1">1.200</td><td align="left" rowspan="1" colspan="1">0.446</td><td align="left" rowspan="1" colspan="1">1.010</td><td align="left" rowspan="1" colspan="1">0.984</td><td align="left" rowspan="1" colspan="1">1.038</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Gender Female vs. Male</td><td align="left" rowspan="1" colspan="1">0.541</td><td align="left" rowspan="1" colspan="1">0.470</td><td align="left" rowspan="1" colspan="1">0.802</td><td align="left" rowspan="1" colspan="1">0.441</td><td align="left" rowspan="1" colspan="1">1.459</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Histological type U vs. D</td><td align="left" rowspan="1" colspan="1">0.147</td><td align="left" rowspan="1" colspan="1">0.607</td><td align="left" rowspan="1" colspan="1">0.809</td><td align="left" rowspan="1" colspan="1">0.360</td><td align="left" rowspan="1" colspan="1">1.818</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical classification II- IVb vs. I</td><td align="left" rowspan="1" colspan="1">26.083</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<sup>&#x025b3;</sup>
</td><td align="left" rowspan="1" colspan="1">3.217</td><td align="left" rowspan="1" colspan="1">2.045</td><td align="left" rowspan="1" colspan="1">5.062</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">sCXCL5 level High vs. Low</td><td align="left" rowspan="1" colspan="1">5.970</td><td align="left" rowspan="1" colspan="1">0.014</td><td align="left" rowspan="1" colspan="1">2.008</td><td align="left" rowspan="1" colspan="1">1.145</td><td align="left" rowspan="1" colspan="1">3.523</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>&#x025b3;, adjusted P-values &#x0003c;0.017 were considered statistically significant. Abbreviations: OS, overall survival; NPC, nasopharyngeal carcinoma; sCXCL5, serum CXCL5; D, differentiated non-keratinized carcinoma; U, undifferentiated non-keratinized carcinoma; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3e"><title>The Prognostic Score Model</title><p>Based on the above analysis, we built a new prognostic score model that utilized both NPC clinical classification and sCXCL5 level (C-C model) to predict NPC prognosis in the training set. Based on the hazard ratio derived from the multivariate analysis for OS, a score of 1 to 3 was assigned to clinical classification and a score of 1 to 2 was assigned to sCXCL5 level. Because the survival rates for the class I and II NPC patients were not significantly different (100% for clinical class I vs. 92% for clinical class II, <italic>P</italic>&#x0200a;=&#x0200a;0.648), a score of 1 was assigned to both clinical classification I and clinical classification II. The total scores for each patient were calculated by adding the two scores together; therefore, the total scores ranged from 2 to 5 (mean&#x0200a;=&#x0200a;3.7 and median&#x0200a;=&#x0200a;4). The patients were divided into 4 risk subgroups based on their total score: low risk (L, score 2, 11.0% of all 290 patients); intermediate-low risk (IL, score 3, 26.9% of all 290 patients); intermediate-high risk (IH, scores 4, 42.8% of all 290 patients) and high risk (H, score 5, 19.3% of all 290 patients).</p><p>We further performed survival analyses for the patients in the training set, the testing set and all of the patients combined, with the results indicating that the OS, DMFS, LRRFS, and PFS curves discriminated between the four risk subgroups in the C-C model more clearly than clinical classification alone. In the training set, the 6-year-OS rates were 100%, 79%, 61%, and 27% for the L, IL, IH and H risk groups, respectively. These rates were 100%, 92%, 70%, and 41% for clinical class I, II, III and IVa-b patients, respectively (<xref ref-type="table" rid="pone-0057830-t004">Table 4</xref>; <xref ref-type="fig" rid="pone-0057830-g002">Figures 2</xref>, <xref ref-type="fig" rid="pone-0057830-g003">3</xref>, <xref ref-type="fig" rid="pone-0057830-g004">4</xref> show the complete follow-up). The C-Indices for clinical classification in the training set and testing set were 0.742 and 0.733, respectively, while these values were 0.751 and 0.762 for the C-C model. These results confirmed that the C-C model was more precise in predicting the prognosis of NPC patients than clinical classification alone.</p><fig id="pone-0057830-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057830.g002</object-id><label>Figure 2</label><caption><title>The C-C model-derived survival curves for the nasopharyngeal carcinoma patients in the training set.</title><p>The follow-up prognoses of the nasopharyngeal carcinoma patients in the training set were clearly identified by the four risk subgroups of the C-C model. (A) The overall survival curves for the L, IL, IH, and H risk subgroups of the C-C model; (B) The distant metastasis-free survival curves for the L, IL, IH, and H risk subgroups of the C-C model; (C) The progression-free survival curves for the L, IL, IH, and H risk subgroups of the C-C model; and (D) The local-regional recurrence-free survival curves for the L, IL, IH, and H risk subgroups of the C-C model. L, low-risk, n&#x0200a;=&#x0200a;16; IL, intermediate-low-risk, n&#x0200a;=&#x0200a;39; IH, intermediate-high-risk, n&#x0200a;=&#x0200a;62; H, high-risk, n&#x0200a;=&#x0200a;28.</p></caption><graphic xlink:href="pone.0057830.g002"/></fig><fig id="pone-0057830-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057830.g003</object-id><label>Figure 3</label><caption><title>The C-C model-derived survival curves for the nasopharyngeal carcinoma patients in the testing set.</title><p>The follow-up prognoses of the nasopharyngeal carcinoma patients in the testing set were clearly identified by the four risk subgroups of the C-C model. (A) The overall survival curves for the L, IL, IH, and H risk subgroups of the C-C model; (B) The distant metastasis-free survival curves for the L, IL, IH, and H risk subgroups of the C-C model; (C) The progression-free survival curves for the L, IL, IH, and H risk subgroups of the C-C model; and (D) The local-regional recurrence-free survival curves for the L, IL, IH, and H risk subgroups of the C-C model. L, low risk, n&#x0200a;=&#x0200a;8; IL, intermediate-low risk, n&#x0200a;=&#x0200a;38; IH, intermediate-high risk, n&#x0200a;=&#x0200a;68; H, high risk, n&#x0200a;=&#x0200a;31.</p></caption><graphic xlink:href="pone.0057830.g003"/></fig><fig id="pone-0057830-g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057830.g004</object-id><label>Figure 4</label><caption><title>The C-C model-derived survival curves for all 290 nasopharyngeal carcinoma patients.</title><p>The follow-up prognoses of all 290 nasopharyngeal carcinoma patients were clearly identified by the four risk subgroups of C-C model. (A) The overall survival curves for the L, IL, IH, and H risk subgroups of the C-C model; (B) The distant metastasis-free survival curves for the L, IL, IH, and H risk subgroups of the C-C model; (C) The progression-free survival curves for the L, IL, IH, and H risk subgroups of the C-C model; and (D) The local-regional recurrence-free survival curves for the L, IL, IH, and H risk subgroups of the C-C model. L, low risk, n&#x0200a;=&#x0200a;24; IL, intermediate-low risk, n&#x0200a;=&#x0200a;77; IH, intermediate-high risk, n&#x0200a;=&#x0200a;130; H, high-risk, n&#x0200a;=&#x0200a;59.</p></caption><graphic xlink:href="pone.0057830.g004"/></fig><table-wrap id="pone-0057830-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057830.t004</object-id><label>Table 4</label><caption><title>The C-C model-derived 6-year OS, DMFS, PFS, and LRRFS for the L, IL, IH, and H risk patient groups.</title></caption><alternatives><graphic id="pone-0057830-t004-4" xlink:href="pone.0057830.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">6-yearsurvival (%)</td><td colspan="5" align="left" rowspan="1">Training set (n&#x0200a;=&#x0200a;145)</td><td colspan="5" align="left" rowspan="1">Testing set (n&#x0200a;=&#x0200a;145)</td><td colspan="5" align="left" rowspan="1">All patients (n&#x0200a;=&#x0200a;290)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">L</td><td align="left" rowspan="1" colspan="1">IL</td><td align="left" rowspan="1" colspan="1">IH</td><td align="left" rowspan="1" colspan="1">H</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
</td><td align="left" rowspan="1" colspan="1">L</td><td align="left" rowspan="1" colspan="1">IL</td><td align="left" rowspan="1" colspan="1">IH</td><td align="left" rowspan="1" colspan="1">H</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
</td><td align="left" rowspan="1" colspan="1">L</td><td align="left" rowspan="1" colspan="1">IL</td><td align="left" rowspan="1" colspan="1">IH</td><td align="left" rowspan="1" colspan="1">H</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">OS</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">DMFS</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">89</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">PFS</td><td align="left" rowspan="1" colspan="1">88</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LRRFS</td><td align="left" rowspan="1" colspan="1">88</td><td align="left" rowspan="1" colspan="1">88</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">94</td><td align="left" rowspan="1" colspan="1">89</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>Abbreviations: OS, overall survival; DMFS, distant metastasis-free survival; PFS, progression-free survival; LRRFS, local&#x02013;regional recurrence-free survival; L, low risk group; IL, intermediate-low risk; IH, intermediate-high risk; H, high-risk.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>In this study, we were the first to determine the sCXCL5 concentrations of NPC patients and analyze the associations between sCXCL5 levels and clinicopathological characteristics and prognosis. A high sCXCL5 level was associated with advanced lymph node classification, distant metastasis and tumor progression, findings that were verified in the testing set. We found that the OS and DMFS of NPC patients with high sCXCL5 levels were significantly poorer than the OS and DMFS of NPC patients with low sCXCL5 levels. The multivariate analysis further confirmed that clinical classification and sCXCL5 level were independent predictors of the OS, DMFS and PFS of NPC patients. We used clinical classification and sCXCL5 levels to build a novel statistical model (C-C model) to predict the prognosis of NPC patients. The C-C model classified NPC patients into 4 risk subgroups and was more effective in predicting the prognosis for NPC patients than clinical classification alone. This analysis also indicated that sCXCL5 level is an independent prognostic factor for NPC patients and that the C-C model could be applied in clinical practice to achieve a more accurate prognostic prediction than clinical classification alone. Thus, the use of this model in clinical practice would facilitate the individualized treatment of NPC patients in the future.</p><p>Various chemokines play important roles in the regulation of tumor progression. CXCL5 belongs to the glutamic acid-leucine-arginine (ELR) tripeptide motif cysteine-X-cysteine (CXC) chemokines. Depending on the presence or absence of the ELR motif at the NH<sub>2</sub> terminus of the protein, CXC chemokines can be further classified as ELR-positive (ELR+) or ELR-negative (ELR&#x02212;), respectively. The former can bind to CXC chemokine-receptor 2 (CXCR2). Because these molecules are mediators of angiogenesis <xref rid="pone.0057830-Bizzarri1" ref-type="bibr">[21]</xref>, the expression of ELR+ and CXCR2 is associated with tumor progression <xref rid="pone.0057830-Mestas1" ref-type="bibr">[22]</xref>&#x02013;<xref rid="pone.0057830-White1" ref-type="bibr">[25]</xref>. Miyazaki et al. <xref rid="pone.0057830-Miyazaki1" ref-type="bibr">[14]</xref> found the transcriptional up-regulation of CXCL5 in the metastatic lymph nodes of head and neck squamous cell carcinoma patients. Park et al. <xref rid="pone.0057830-Park1" ref-type="bibr">[18]</xref> also reported that CXCL5 overexpression was associated with the lymph node metastasis of gastric cancer. Our current data similarly found an association between high sCXCL5 levels and advanced N classification. Studies have confirmed that high levels of CXCL5 are associated with high metastatic potential and poor survival rates in prostate cancer, colorectal cancer, hepatocellular carcinoma, and oral squamous cancers <xref rid="pone.0057830-Kuo1" ref-type="bibr">[13]</xref>&#x02013;<xref rid="pone.0057830-Zhou1" ref-type="bibr">[16]</xref>, <xref rid="pone.0057830-Begley1" ref-type="bibr">[19]</xref>. In our study, we also found that NPC patients with high sCXCL5 levels developed more distant metastasis events and exhibited a more aggressive disease progression after treatment than patients with low sCXCL5 levels. This finding suggested that the pro-angiogenic property of CXCL5 might play an important role in the metastasis of NPC. To our knowledge, this study is the first report to evaluate the significance of sCXCL5 levels in the prognosis of NPC patients.</p><p>Several statistical prediction models have been proposed for metastatic NPC patients. For example, Tan et al. developed a new prognostic index score that utilized performance status, hemoglobin, disease-free interval months, and metastasis status at initial diagnosis and was useful in prognosticating and stratifying patients with disseminated NPC <xref rid="pone.0057830-Ong1" ref-type="bibr">[26]</xref>, <xref rid="pone.0057830-Toh1" ref-type="bibr">[27]</xref>. Jin et al. <xref rid="pone.0057830-Jin1" ref-type="bibr">[28]</xref> reported that a model built with hemoglobin, lactate dehydrogenase, alkaline phosphatase, Epstein&#x02013;Barr virus DNA, and performance status could help guide the prognostication of metastatic NPC patients in epidemic areas. Cao et al. <xref rid="pone.0057830-Cao1" ref-type="bibr">[29]</xref> found that a risk subset composed of viral capsid antigen-IgA titer, number of metastases, and secondary metastases may provide a more accurate and appropriate assessment of the prognosis for NPC patients with lung metastasis. However, clinical classification is widely used to predict the prognosis for non-metastatic NPC patients in clinical practice, despite the inaccuracy in predictions due to the heterogeneity of NPC. Statistical prediction models that included inflammatory biomarkers for non-metastatic NPC patients are rare. One such model used age, WHO histological type, serum lactate dehydrogenase, and tumor locations to predict local-regional control of non-disseminated NPC <xref rid="pone.0057830-Cheng1" ref-type="bibr">[30]</xref>. With the development of radiochemotherapy, the survival rate of NPC patients has improved significantly, but local-regional relapse and distant metastasis remain the major reasons for treatment failure in NPC patients. The ability to identify those patients with a very poor prognosis and high potential for metastasis before treatment is an urgent clinical problem.</p><p>In the current study, we built a novel C-C prognostic model from the patients in the training set by combining sCXCL5 level and clinical classification as parameters to predict the prognosis of NPC patients. The testing set was then used to verify the accuracy of this statistical model. We can better predict the disease progression and survival of NPC patients with the C-C model than with clinical classification alone. The C-Indices of clinical classification were lower than the C-Indices of the C-C model, as shown in the results. The survival curves for OS, DMFS, and PFS survival curves for the four risk subgroups of the C-C model were clearly distinguishable in the training set, the testing set, and a set containing all of the patients. With the exception of some overlap between the L and IL risk groups, the LRRFS can also be clearly discriminated with the C-C model. This finding strongly suggested that the new statistical model that used both sCXCL5 levels and the clinical classification system to accurately predict the prognosis of NPC patients was accurate and helpful in clinical practice.</p><p>However, we acknowledge that much more needs to be clarified before this model is eventually applied in clinical practice. For example, it will be interesting to investigate the correlation between sCXCL5 expression and functional changes in NPC tissue specimens, e.g., angiogenesis (blood vessel density) or Epstein-Barr virus infection status. We will incorporate these data into the statistical C-C model in future studies to better predict the risk of disease progression in NPC patients.</p></sec></body><back><ack><p>The blood samples were provided by the tumor resource storehouse of Sun Yat-Sen University Cancer Center. We thank Xin-Jian Li, Li-Xia Peng, Fang-Jing Zheng, Ying-Ying Liang, and Xue Cao of the State Key Laboratory of Oncology in Southern China for their assistance with the experiments.</p></ack><ref-list><title>References</title><ref id="pone.0057830-Wei1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Wei</surname><given-names>WI</given-names></name>, <name><surname>Sham</surname><given-names>JS</given-names></name> (<year>2005</year>) <article-title>Nasopharyngeal carcinoma</article-title>. <source>Lancet</source>
<volume>365</volume>: <fpage>2041</fpage>&#x02013;<lpage>2054</lpage>.<pub-id pub-id-type="pmid">15950718</pub-id></mixed-citation></ref><ref id="pone.0057830-Fang1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Fang</surname><given-names>CY</given-names></name>, <name><surname>Lee</surname><given-names>CH</given-names></name>, <name><surname>Wu</surname><given-names>CC</given-names></name>, <name><surname>Chang</surname><given-names>YT</given-names></name>, <name><surname>Yu</surname><given-names>SL</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cells</article-title>. <source>Int J Cancer</source>
<volume>124</volume>: <fpage>2016</fpage>&#x02013;<lpage>2025</lpage>.<pub-id pub-id-type="pmid">19132751</pub-id></mixed-citation></ref><ref id="pone.0057830-Endo1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Endo</surname><given-names>K</given-names></name>, <name><surname>Kondo</surname><given-names>S</given-names></name>, <name><surname>Shackleford</surname><given-names>J</given-names></name>, <name><surname>Horikawa</surname><given-names>T</given-names></name>, <name><surname>Kitagawa</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration</article-title>. <source>Oncogene</source>
<volume>28</volume>: <fpage>1725</fpage>&#x02013;<lpage>1735</lpage>.<pub-id pub-id-type="pmid">19234486</pub-id></mixed-citation></ref><ref id="pone.0057830-Lee1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Lee</surname><given-names>AWM</given-names></name>, <name><surname>Lau</surname><given-names>WH</given-names></name>, <name><surname>Tung</surname><given-names>SY</given-names></name>, <name><surname>Chua</surname><given-names>DTT</given-names></name>, <name><surname>Chappell</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group</article-title>. <source>J Clin Oncol</source>
<volume>23</volume>: <fpage>6966</fpage>&#x02013;<lpage>6975</lpage>.<pub-id pub-id-type="pmid">16192584</pub-id></mixed-citation></ref><ref id="pone.0057830-Lai1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Lai</surname><given-names>SZ</given-names></name>, <name><surname>Li</surname><given-names>WF</given-names></name>, <name><surname>Chen</surname><given-names>L</given-names></name>, <name><surname>Luo</surname><given-names>W</given-names></name>, <name><surname>Chen</surname><given-names>YY</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>How Does Intensity-Modulated Radiotherapy Versus Conventional Two-Dimensional Radiotherapy Influence the Treatment Results in Nasopharyngeal Carcinoma Patients?</article-title>. <source>Int J Radiat Oncol Biol Phys</source>
<volume>80</volume>: <fpage>661</fpage>&#x02013;<lpage>668</lpage>.<pub-id pub-id-type="pmid">20643517</pub-id></mixed-citation></ref><ref id="pone.0057830-Ma1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Ma</surname><given-names>J</given-names></name>, <name><surname>Mai</surname><given-names>HQ</given-names></name>, <name><surname>Hong</surname><given-names>MH</given-names></name>, <name><surname>Min</surname><given-names>HQ</given-names></name>, <name><surname>Mao</surname><given-names>ZD</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Long-Term Results of a Prospective Randomized Trial Comparing Neoadjuvant Chemotherapy Plus Radiotherapy with Radiotherapy Alone for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma</article-title>. <source>Ai Zheng</source>
<volume>20</volume>: <fpage>505</fpage>&#x02013;<lpage>510</lpage>.</mixed-citation></ref><ref id="pone.0057830-Lee2"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Lee</surname><given-names>AWM</given-names></name>, <name><surname>Sze</surname><given-names>WM</given-names></name>, <name><surname>Au</surname><given-names>JSK</given-names></name>, <name><surname>Leung</surname><given-names>SF</given-names></name>, <name><surname>Leung</surname><given-names>TW</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience</article-title>. <source>Int J Radiat Oncol Biol Phys</source>
<volume>61</volume>: <fpage>1107</fpage>&#x02013;<lpage>1116</lpage>.<pub-id pub-id-type="pmid">15752890</pub-id></mixed-citation></ref><ref id="pone.0057830-Lu1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Lu</surname><given-names>X</given-names></name>, <name><surname>Qian</surname><given-names>CN</given-names></name>, <name><surname>Mu</surname><given-names>YG</given-names></name>, <name><surname>Li</surname><given-names>NW</given-names></name>, <name><surname>Li</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Serum CCL2 and serum TNF-&#x003b1; &#x02013; Two new biomarkers predict bone invasion, post-treatment distant metastasis and poor overall survival in nasopharyngeal carcinoma</article-title>. <source>Eur J Cancer</source>
<volume>47</volume>: <fpage>339</fpage>&#x02013;<lpage>346</lpage>.<pub-id pub-id-type="pmid">20951575</pub-id></mixed-citation></ref><ref id="pone.0057830-Xu1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Wan</surname><given-names>XB</given-names></name>, <name><surname>Huang</surname><given-names>XF</given-names></name>, <name><surname>Chan</surname><given-names>KCA</given-names></name>, <name><surname>Hong</surname><given-names>MH</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Serologic Antienzyme Rate of Epstein-Barr Virus DNase-Specific Neutralizing Antibody Segregates TNM Classification in Nasopharyngeal Carcinoma</article-title>. <source>J Clin Onco</source>
<volume>l28</volume>: <fpage>5202</fpage>&#x02013;<lpage>5209</lpage>.</mixed-citation></ref><ref id="pone.0057830-Mao1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Mao</surname><given-names>YP</given-names></name>, <name><surname>Li</surname><given-names>WF</given-names></name>, <name><surname>Chen</surname><given-names>L</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>LZ</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>A clinical verification of the Chinese 2008 staging system for nasopharyngeal carcinoma</article-title>. <source>Ai Zheng</source>
<volume>28</volume>: <fpage>1022</fpage>&#x02013;<lpage>1028</lpage>.<pub-id pub-id-type="pmid">19799808</pub-id></mixed-citation></ref><ref id="pone.0057830-Walz1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Walz</surname><given-names>A</given-names></name>, <name><surname>Burgener</surname><given-names>R</given-names></name>, <name><surname>Car</surname><given-names>B</given-names></name>, <name><surname>Baggiolini</surname><given-names>M</given-names></name>, <name><surname>Kunkel</surname><given-names>SL</given-names></name>, <etal>et al</etal> (<year>1991</year>) <article-title>Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8</article-title>. <source>J Exp Med</source>
<volume>174</volume>: <fpage>1355</fpage>&#x02013;<lpage>1362</lpage>.<pub-id pub-id-type="pmid">1744577</pub-id></mixed-citation></ref><ref id="pone.0057830-Koch1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Koch</surname><given-names>AE</given-names></name>, <name><surname>Kunkel</surname><given-names>SL</given-names></name>, <name><surname>Harlow</surname><given-names>LA</given-names></name>, <name><surname>Mazarakis</surname><given-names>DD</given-names></name>, <name><surname>Haines</surname><given-names>GK</given-names></name>, <etal>et al</etal> (<year>1994</year>) <article-title>Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis</article-title>. <source>J Clin Invest</source>
<volume>94</volume>: <fpage>1012</fpage>&#x02013;<lpage>1018</lpage>.<pub-id pub-id-type="pmid">8083342</pub-id></mixed-citation></ref><ref id="pone.0057830-Kuo1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Kuo</surname><given-names>PL</given-names></name>, <name><surname>Chen</surname><given-names>YH</given-names></name>, <name><surname>Chen</surname><given-names>TC</given-names></name>, <name><surname>Shen</surname><given-names>KH</given-names></name>, <name><surname>Hsu</surname><given-names>YL</given-names></name> (<year>2011</year>) <article-title>CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway</article-title>. <source>J Cell Physiol</source>
<volume>226</volume>: <fpage>1224</fpage>&#x02013;<lpage>1231</lpage>.<pub-id pub-id-type="pmid">20945384</pub-id></mixed-citation></ref><ref id="pone.0057830-Miyazaki1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Miyazaki</surname><given-names>H</given-names></name>, <name><surname>Patel</surname><given-names>V</given-names></name>, <name><surname>Wang</surname><given-names>H</given-names></name>, <name><surname>Edmunds</surname><given-names>RK</given-names></name>, <name><surname>Gutkind</surname><given-names>JS</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Down-regulation of CXCL5 Inhibits Squamous Carcinogenesis</article-title>. <source>Cancer Res</source>
<volume>66</volume>: <fpage>4279</fpage>&#x02013;<lpage>4284</lpage>.<pub-id pub-id-type="pmid">16618752</pub-id></mixed-citation></ref><ref id="pone.0057830-Kawamura1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Kawamura</surname><given-names>M</given-names></name>, <name><surname>Toiyama</surname><given-names>Y</given-names></name>, <name><surname>Tanaka</surname><given-names>K</given-names></name>, <name><surname>Saigusa</surname><given-names>S</given-names></name>, <name><surname>Okugawa</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer</article-title>. <source>Eur J Cancer</source>
<volume>48</volume>: <fpage>2244</fpage>&#x02013;<lpage>2251</lpage>.<pub-id pub-id-type="pmid">22197219</pub-id></mixed-citation></ref><ref id="pone.0057830-Zhou1"><label>16</label><mixed-citation publication-type="other">Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, <etal>et al</etal>.. (2012) Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology: in press.</mixed-citation></ref><ref id="pone.0057830-Li1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Li</surname><given-names>A</given-names></name>, <name><surname>King</surname><given-names>J</given-names></name>, <name><surname>Moro</surname><given-names>A</given-names></name>, <name><surname>Sugi</surname><given-names>MD</given-names></name>, <name><surname>Dawson</surname><given-names>DW</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer</article-title>. <source>Am J Pathol</source>
<volume>178</volume>: <fpage>1340</fpage>&#x02013;<lpage>1349</lpage>.<pub-id pub-id-type="pmid">21356384</pub-id></mixed-citation></ref><ref id="pone.0057830-Park1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Park</surname><given-names>JY</given-names></name>, <name><surname>Park</surname><given-names>KH</given-names></name>, <name><surname>Bang</surname><given-names>S</given-names></name>, <name><surname>Kim</surname><given-names>MH</given-names></name>, <name><surname>Lee</surname><given-names>JE</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>CXCL5 overexpression is associated with late classification gastric cancer</article-title>. <source>J Cancer Res Clin Oncol</source>
<volume>133</volume>: <fpage>835</fpage>&#x02013;<lpage>840</lpage>.<pub-id pub-id-type="pmid">17479287</pub-id></mixed-citation></ref><ref id="pone.0057830-Begley1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Begley</surname><given-names>LA</given-names></name>, <name><surname>Kasina</surname><given-names>S</given-names></name>, <name><surname>Mehra</surname><given-names>R</given-names></name>, <name><surname>Adsule</surname><given-names>S</given-names></name>, <name><surname>Admon</surname><given-names>AJ</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>CXCL5 promotes prostate cancer progression</article-title>. <source>Neoplasia (New York, NY)</source>
<volume>10</volume>: <fpage>244</fpage>.</mixed-citation></ref><ref id="pone.0057830-Baier1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Baier</surname><given-names>PK</given-names></name>, <name><surname>Eggstein</surname><given-names>S</given-names></name>, <name><surname>Wolff-Vorbeck</surname><given-names>G</given-names></name>, <name><surname>Baumgartner</surname><given-names>U</given-names></name>, <name><surname>Hopt</surname><given-names>UT</given-names></name> (<year>2005</year>) <article-title>Chemokines in human colorectal carcinoma</article-title>. <source>Anticancer Res</source>
<volume>25</volume>: <fpage>3581</fpage>&#x02013;<lpage>3584</lpage>.<pub-id pub-id-type="pmid">16101183</pub-id></mixed-citation></ref><ref id="pone.0057830-Bizzarri1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Bizzarri</surname><given-names>C</given-names></name>, <name><surname>Beccari</surname><given-names>AR</given-names></name>, <name><surname>Bertini</surname><given-names>R</given-names></name>, <name><surname>Cavicchia</surname><given-names>MR</given-names></name>, <name><surname>Giorgini</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets</article-title>. <source>Pharmacol Therapeut</source>
<volume>112</volume>: <fpage>139</fpage>&#x02013;<lpage>149</lpage>.</mixed-citation></ref><ref id="pone.0057830-Mestas1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Mestas</surname><given-names>J</given-names></name>, <name><surname>Burdick</surname><given-names>MD</given-names></name>, <name><surname>Reckamp</surname><given-names>K</given-names></name>, <name><surname>Pantuck</surname><given-names>A</given-names></name>, <name><surname>Figlin</surname><given-names>RA</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma</article-title>. <source>J Immunol</source>
<volume>175</volume>: <fpage>5351</fpage>.<pub-id pub-id-type="pmid">16210641</pub-id></mixed-citation></ref><ref id="pone.0057830-Fregene1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Fregene</surname><given-names>T</given-names></name>, <name><surname>Khanuja</surname><given-names>P</given-names></name>, <name><surname>Noto</surname><given-names>A</given-names></name>, <name><surname>Gehani</surname><given-names>S</given-names></name>, <name><surname>Van Egmont</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>1993</year>) <article-title>Tumor-associated angiogenesis in prostate cancer</article-title>. <source>Anticancer Res</source>
<volume>13</volume>: <fpage>2377</fpage>.<pub-id pub-id-type="pmid">7510938</pub-id></mixed-citation></ref><ref id="pone.0057830-Samoszuk1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Samoszuk</surname><given-names>M</given-names></name>, <name><surname>Lin</surname><given-names>F</given-names></name>, <name><surname>Rim</surname><given-names>P</given-names></name>, <name><surname>Strathearn</surname><given-names>G</given-names></name> (<year>1996</year>) <article-title>New marker for blood vessels in human ovarian and endometrial cancers</article-title>. <source>Clin Cancer Res</source>
<volume>2</volume>: <fpage>1867</fpage>&#x02013;<lpage>1871</lpage>.<pub-id pub-id-type="pmid">9816142</pub-id></mixed-citation></ref><ref id="pone.0057830-White1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>White</surname><given-names>ES</given-names></name>, <name><surname>Flaherty</surname><given-names>KR</given-names></name>, <name><surname>Carskadon</surname><given-names>S</given-names></name>, <name><surname>Brant</surname><given-names>A</given-names></name>, <name><surname>Iannettoni</surname><given-names>MD</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer</article-title>. <source>Clin Cancer Res</source>
<volume>9</volume>: <fpage>853</fpage>&#x02013;<lpage>860</lpage>.<pub-id pub-id-type="pmid">12576459</pub-id></mixed-citation></ref><ref id="pone.0057830-Ong1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Ong</surname><given-names>YK</given-names></name>, <name><surname>Heng</surname><given-names>DM</given-names></name>, <name><surname>Chung</surname><given-names>B</given-names></name>, <name><surname>Leong</surname><given-names>SS</given-names></name>, <name><surname>Wee</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Design of a prognostic index score for metastatic nasopharyngeal carcinoma</article-title>. <source>Eur J Cancer</source>
<volume>39</volume>: <fpage>1535</fpage>&#x02013;<lpage>1541</lpage>.<pub-id pub-id-type="pmid">12855259</pub-id></mixed-citation></ref><ref id="pone.0057830-Toh1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Toh</surname><given-names>CK</given-names></name>, <name><surname>Heng</surname><given-names>D</given-names></name>, <name><surname>Ong</surname><given-names>YK</given-names></name>, <name><surname>Leong</surname><given-names>SS</given-names></name>, <name><surname>Wee</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma</article-title>. <source>Br J Cancer</source>
<volume>92</volume>: <fpage>1382</fpage>&#x02013;<lpage>1387</lpage>.<pub-id pub-id-type="pmid">15812546</pub-id></mixed-citation></ref><ref id="pone.0057830-Jin1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Jin</surname><given-names>Y</given-names></name>, <name><surname>Cai</surname><given-names>XY</given-names></name>, <name><surname>Cai</surname><given-names>YC</given-names></name>, <name><surname>Cao</surname><given-names>Y</given-names></name>, <name><surname>Xia</surname><given-names>Q</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area</article-title>. <source>Eur J Cancer</source>
<volume>48</volume>: <fpage>882</fpage>&#x02013;<lpage>888</lpage>.<pub-id pub-id-type="pmid">22030451</pub-id></mixed-citation></ref><ref id="pone.0057830-Cao1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Cao</surname><given-names>X</given-names></name>, <name><surname>Luo</surname><given-names>RZ</given-names></name>, <name><surname>He</surname><given-names>LR</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Lin</surname><given-names>WQ</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Prognosticators and Risk Grouping in Patients with Lung Metastasis from Nasopharyngeal Carcinoma: A more accurate and appropriate assessment of prognosis</article-title>. <source>Radiat Oncol</source>
<volume>6</volume>: <fpage>104</fpage>.<pub-id pub-id-type="pmid">21871101</pub-id></mixed-citation></ref><ref id="pone.0057830-Cheng1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Cheng</surname><given-names>SH</given-names></name>, <name><surname>Tsai</surname><given-names>SY</given-names></name>, <name><surname>Horng</surname><given-names>CF</given-names></name>, <name><surname>Yen</surname><given-names>KL</given-names></name>, <name><surname>Jian</surname><given-names>JJ</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>A prognostic scoring system for locoregional control in nasopharyngeal carcinoma following conformal radiotherapy</article-title>. <source>Int J Radiat Oncol Biol Phys</source>
<volume>66</volume>: <fpage>992</fpage>&#x02013;<lpage>1003</lpage>.<pub-id pub-id-type="pmid">16979832</pub-id></mixed-citation></ref></ref-list></back></article>